Inotek has sponsored Phase 1, Phase 2 and Phase 3 clinical trials for trabodenoson monotherapy which have concluded, as well as a Phase 2 clinical trial for trabodenoson + latanoprost in a fixed-dose combination. Click the links below to learn more about each trial through clinicaltrials.gov.
Identifier | Status | Therapy | Study Name |
---|---|---|---|
NCT02829996 | Completed | Fixed-dose combination | Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma |
NCT02565173 | Completed | Trabodenoson monotherapy | Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma |
NCT01917383 | Completed | Trabodenoson monotherapy | A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma |
NCT01123785 | Completed | Trabodenoson monotherapy | A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma |
NCT01123772 | Completed | Trabodenoson monotherapy | Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers |